Interleukin-13 promoter gene polymorphism -1112C/T is associated with the systemic form of mastocytosis
Article first published online: 13 JAN 2009
© 2009 The Authors. Journal compilation © 2009 Blackwell Munksgaard
Volume 64, Issue 2, pages 287–294, February 2009
How to Cite
Nedoszytko, B., Niedoszytko, M., Lange, M., Van Doormaal, J., Gleń, J., Zabłotna, M., Renke, J., Vales, A., Buljubasic, F., Jassem, E., Roszkiewicz, J. and Valent, P. (2009), Interleukin-13 promoter gene polymorphism -1112C/T is associated with the systemic form of mastocytosis. Allergy, 64: 287–294. doi: 10.1111/j.1398-9995.2008.01827.x
- Issue published online: 21 JAN 2009
- Article first published online: 13 JAN 2009
- Accepted for publication 18 May 2008
- gene polymorphism;
Background: Mastocytosis is a heterogenous disease involving mast cells (MC) and their progenitors. Cutaneous and systemic variants of the disease have been reported. In contrast to cutaneous mastocytosis (CM), patients with systemic mastocytosis (SM) are at risk to develop disease progression or a nonMC-lineage haematopoietic neoplasm. Little is known, however, about factors predisposing for the development of SM. One factor may be cytokine regulation of MC progenitors.
Methods: We examined the role of the interleukin-13 (IL-13) promoter gene polymorphism -1112C/T, known to be associated with increased transcription, in mastocytosis using allele-specific polymerase chain reaction method. Serum tryptase and IL-13 levels were determined by immunoassay, and expression of the IL-13 receptor in neoplastic MC by reverse transcription-polymerase chain reaction and flow cytometry.
Results: The frequency of the -1112T allele of the IL-13 promoter was significantly higher in patients with SM compared with CM (P < 0.008) and in mastocytosis patients compared with healthy controls (P < 0.0001). Correspondingly, the polymorphism was found to correlate with an elevated serum tryptase level (P = 0.004) and with adult-onset of the disease (P < 0.0015), both of which are almost invariably associated with SM. Serum IL-13 levels were also higher in SM patients compared with CM (P = 0.011), and higher in CT- than in CC carriers (P < 0.05). Finally, we were able to show that neoplastic human MC display IL-13 receptors and grow better in IL-13-containing medium.
Conclusions: The -1112C/T IL-13 gene polymorphism and the resulting ‘hypertranscription’ may predispose for the development of SM.